

RNS REACH | 14 March 2024



Immupharma PLC
("Immupharma" or the "Company")

IMMUPHARMA AT BIO-EUROPE SPRING 2024
18-20 March 2024 | Barcelona

Immupharma PLC (LSE:IMM), the specialist drug discovery and development company, announces that Tim McCarthy, CEO and Dr Tim Franklin, COO, will be attending BIO-Europe Spring. The event will be held between 18-20 March 2024, in Barcelona.

BIO-Europe Spring is the premier springtime partnering event, designed to provide biotechnology companies with the opportunity to present to and connect with investors together with the global biopharma community.

Commenting on the event, Tim McCarthy, CEO of Immupharma said: *"Following on from our recent announcements, including moving our lead asset P140 for SLE (Lupuzor™) forward, with our appointed CRO, Simbec-Orion, in parallel with our CIDP program, we are delighted to have BIO-Europe as the next key platform in 2024 to present our unique portfolio to key industry and investment specialists. Our focus will be to secure partnering opportunities across our programs including our P140 platform and our earlier stage but highly exciting anti-infective asset, BioAMB."*

For further information please contact:

Immupharma PLC (www.immupharma.co.uk)	+44 (0) 207 206 2650
Tim McCarthy, Chief Executive Officer Lisa Baderoon, Head of Investor Relations	+ 44 (0) 7721 413496
SPARK Advisory Partners Limited (NOMAD) Neil Baldwin	+44 (0) 203 368 3550
Stanford Capital Partners (Joint Broker) Patrick Claridge, Bob Pountney	+44 (0) 203 650 3650
SI Capital (Joint Broker) Nick Emerson	+44 (0) 1483 413500

Notes to Editors

About Immupharma PLC

Immupharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140/SLE (Lupuzor™), P140 "restores" the immune system back to normal, by enabling tolerogenic antigen presenting cells to function properly. **P140 is not an immunosuppressant unlike other molecules in development.** P140 is extremely safe, well-tolerated and patient friendly, and potentially can be self-administered through a subcutaneous injection, once a month for

patient-friendly, and potentially can be self-administered through a subcutaneous injection, once a month for SLE.

For additional information about ImmuPharma please visit www.immupharma.co.uk

ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.

About BIO-Europe Spring, Barcelona, 2024

Connecting the global biopharma community to elevate life science partnerships.

BIO-Europe Spring, is the premier springtime partnering event, bringing together over 3,700 attendees from 2,000+ companies to engage in 20,000 one-to-one meetings.

For more information go to: <https://informaconnect.com/bioeurope-spring/>

About Reach announcements

Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRAJJPMTMTBBBPI